merbarone

01/01/1991 - "Characterization of the urinary metabolites of merbarone in cancer patients."
05/15/1989 - "Merbarone has previously been shown to have antitumor activity of unknown mechanism in P388 and L1210 tumor models (A. "
04/01/2006 - "Studies were carried out to address possible cellular mechanisms by which merbarone, a catalytic inhibitor of DNA topoisomerase II, can block tumor cell growth without inducing extensive DNA cleavage. "
04/01/2006 - "These results provide evidence that merbarone can induce rapid disorganization of DNA in tumor cells that have a functional mitochondrial apoptosis pathway without inducing extensive DNA cleavage."
01/01/1991 - "Phase-I clinical trials in cancer patients of merbarone (MB), a thiobarbituric acid derivative with curative activity against the murine leukemias, were recently completed. "

08/01/1993 - "Phase II trial of merbarone in pancreatic carcinoma. "
01/01/1993 - "No complete or partial responses were observed, and only one minor response was documented, suggesting that merbarone is ineffective against pancreatic cancer at the doses and schedule in which it was administered in this trial."
08/01/1993 - "Merbarone in this dose and schedule has minimal activity in pancreatic cancer."

11/01/1992 - "Phase II trial of merbarone in soft tissue sarcoma. "
11/01/1992 - "Merbarone in this dose and schedule has minimal activity in soft tissue sarcoma."
11/01/1992 - "Thirty-seven patients with advanced soft tissue sarcoma were treated with merbarone utilizing a daily intravenous schedule for five days. "
01/01/1987 - "Merbarone was developed to clinical trial stage on the basis of its 'curative' activity against P388 and L1210 leukemias and moderate activity against B16 melanoma and M5076 sarcoma. "
02/15/1990 - "Merbarone, a nonsedating derivative of thiobarbituric acid, has demonstrated excellent activity against certain murine tumors, including L1210 and P388 leukemias, B16 melanoma, and M5076 sarcoma. "

01/01/1994 - "We treated 16 patients with advanced gastric carcinoma in a phase II study of merbarone. "
10/01/1995 - "In this pretreated population with recurrent squamous cervical carcinoma, merbarone exhibited only minimal activity."
01/01/1994 - "Our data suggest that merbarone at this dose and schedule is inactive against gastric carcinoma. "
01/01/1994 - "Phase II study of merbarone (NSC 336628) in patients with advanced gastric carcinoma."

01/01/1993 - "A phase II study of merbarone in patients with adenocarcinoma of the pancreas."
08/01/1993 - "Twenty-nine patients with advanced pancreatic adenocarcinoma were treated with merbarone, utilizing a daily intravenous schedule for 5 days. "
01/01/1993 - "Merbarone, a nonsedating derivative of thiobarbituric acid that has demonstrated antineoplastic activity against a variety of murine tumors, was evaluated in a phase II trial in patients with advanced, measurable adenocarcinoma of the pancreas. "